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cartilage extracts. The dog ACLT model of acute injury showed
higher levels of TN-C in surgery knees at 1-month post surgery
(73-fold) and 3-months post surgery (48-fold) as compared to
control knees. Higher levels of TN-C were maintained in surgery
knees 6-months post surgery in this dog model. In the rat meniscal
tear model, there was a signiﬁcant increase (40-fold) in TN-C in
surgery knees at 1wk as compared to no surgery contralateral
controls, and this increase was maintained at 4 and 8 wks, albeit
with a smaller absolute difference from control.
Conclusions: The potential of TN-C Large as a unique biomarker
of joint disease/injury has been demonstrated using synovial ﬂuids
from humans with various joint diseases and from preclinical
animal models of joint injury. Being elastic, TN-C might play
an important role in degenerative/regenerative processes where
the normal biomechanical environment of musculoskeletal tissue
is compromised by disease/injury. As a binder of several ECM
proteins, release of TN-C could have a larger impact on the integral
structure/function of other ECM proteins, and has the potential to
be a marker of joint pathobiology and healing. Our preliminary
results indicate that TN-C levels may be applicable to determining
pharmacodynamic activity of chondro-protecting drugs in humans.
Work is ongoing to study the levels of TN-C during degeneration
in other joint tissues such as tendon. Understanding the functions
of TN-C would provide insights for pharmacologic intervention of
musculoskeletal diseases/injuries.
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Purpose: Type II collagen biomarkers have shown promise in the
study of osteoarthritis. CPII (cleaved C-propeptide of type II colla-
gen) has been directly correlated with type II collagen synthesis.
CTX II (crosslinked C-telopeptide fragments of type II collagen),
C1,2C (neoepitope of types I and II collagen created after collage-
nase cleavage), and C2C (neoepitope of type II collagen created
after collagenase cleavage) have been used to assess collagen
degradation. The objective of the study was to compare type II
collagen degradation to synthesis ratios in serum and synovial
ﬂuid (SF) from normal horses and those with osteochondral (OC)
injury.
Methods: SF was taken from the carpal joints of 2 groups of
Thoroughbred racehorses: (1) normal, adult horses > 3 years of
age (2) OC injured horses 2-7 years of age undergoing arthro-
scopic surgery for removal of OC fragments resulting from racing
injury. From group 1 horses, serum was collected from 16 horses.
SF was obtained from 10 middle carpal joints (MCJ), and 10
radiocarpal joints (RCJ). From group 2, serum was collected from
20 horses. SF was collected from 10 MCJ and 10 RCJ. SF
was aseptically collected by needle arthrocentesis without lavage,
Abstract 115 – Table 1. Mean (± SD) concentrations of serum and SF type II collagen biomarkers and degradation to synthesis ratios for normal and osteochondral
(OC) injured carpal joints
Mean biomarker concentrations (± SD) Degradation:Synthesis
C2C (pmol/mL) C1,2C (pmol/mL) CTX II (pg/mL) CPII (ng/mL) C2C:CP II C1,2C:CP II CTX II:CP II
Serum
Normal 479±32.2 452±16*** 70.3±9.0** 1045±91 0.43±0.19 0.47±0.14* 0.07±0.03**
OC injured 415±9.8 580±21.6 39.6±3.4 1019±90 0.43±0.12 0.63±0.21 0.04±0.01
Synovial Fluid
Normal 274±15.6** 278±31.6*** 160±45*** 1013±60*** 0.26±0.06 0.22±0.05*** 0.08±0.05***
OC injured 409±32.6 1070±122 513±47.1 1637±110 0.26±0.09 0.65±0.37 0.37±0.28
Bolded values indicate a signiﬁcant difference between groups within serum or SF. *P≤0.05; **P≤0.01; ***P≤0.001.
centrifuged, and decanted. Commercially available ELISAs, were
used to measure type II collagen markers (C1,2C, C2C, CPII, and
CTX II). Differences between each group were evaluated using an
unpaired t-test. P<0.05 was considered signiﬁcant.
Results: Concentrations of C2C; C1,2C; and CTX II were all sig-
niﬁcantly higher in SF from OC injured joints compared to normal
joints (Table 1). Concentrations of CPII were also signiﬁcantly
higher in SF from injured joints compared to normal joints. Degra-
dation to synthesis ratios in SF were signiﬁcantly higher in OC
injured carpal joints compared to normal joints for C1,2C:CPII and
CTX II:CPII, but not for C2C:CPII. In serum, concentrations of
C1,2C were signiﬁcantly higher from OC injured horses compared
to normal horses. Serum concentrations of CTX II were signiﬁ-
cantly lower from OC injured horses compared to normal horses.
Serum ratios were signiﬁcantly higher in horses with OC injured
carpal joints compared to normal horses for C1,2C:CPII only. The
ratio was signiﬁcantly lower in serum from horses with OC injured
carpal joints compared to normal horses for CTX II:CPII only.
Conclusions: Joint injury affects concentrations of type II colla-
gen degradation and synthesis biomarkers and their ratios when
compared to normal horses. In SF, C1,2C:CPII and CTX II:CPII
ratios demonstrate that degradation predominates over synthe-
sis when the joint is injured because the ratios are higher than
normal joints. The serum C1,2C:CPII ratio suggests that there is
higher degradation after injury compared to normal horses with
no difference in the amount of synthesis. The CTX II:CPII ratio
suggests that the synthesis of type II collagen stays steady with
less degradation. However, increasing or decreasing degradation
to synthesis ratios must be interpreted in light of the known effect
of injury on biomarker concentrations in both SF and serum. Injury
may cause increase in SF concentrations, but may at the same
time cause an increase or decrease in serum concentrations.
Thus, SF biomarkers may be more indicative of degradation or
synthesis in a single joint than serum biomarkers.
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Purpose: Uric acid (UA) is constitutively present in normal cells,
increased in concentration when cells are injured and released
from dying cells. The products of cell stress and tissue damage
may represent “danger signals” that function as endogenous ad-
juvants recognized by the immune system. UA has been identiﬁed
as one of these principal endogenous “danger signals” released
from injured cells. We sought to determine whether elevated syn-
ovial ﬂuid (SF) UA might be a potentiating factor in osteoarthritis
(OA).
Methods: Patients: A total of 159 participants were enrolled in
the Strategies to Predict Osteoarthritis Progression (POP) study.
Informed consent was obtained from all subjects and the entire
study was approved by the Duke University IRB. Participants met
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the ACR criteria for symptomatic OA of at least one knee and
radiographic criteria for OA with a Kellgren-Lawrence (KL) score
of 1-4 in at least one knee.
Radiographic Imaging: Posteroanterior semi-ﬂexed knee radio-
graphs were obtained and read for KL grade and individual radio-
graphic features of OA, including joint space narrowing (JSN) and
osteophytes (OST).
Scintigraphic Imaging: Scintigraphic images of the knee were ob-
tained at 2 mins. (early phase) and 2.5 hrs. (late phase) after in-
jection of technetium-99m methylene diphosphonate. The intensity
of bone uptake was scored for the tibiofemoral and patellofemoral
compartments of each knee.
Biochemical measurements: Matched serum and SF samples
were analyzed for UA using HPLC. Cytokines were measured
in the SF using the Bio-Rad human cytokine multiplex immunoas-
say for IL-5, IL-6, IL-7, IL-8, IL-13, MCP-1, and MIP-1 beta.
Statistical Analysis: Descriptive statistics and univariate analyses
were performed using Graphpad Prism software. Relationships
between SF analytes and OA were analyzed using the GenMOD
procedure with the addition of a repeated statement (GLM, SAS
Enterprise Guide). Multivariate modeling was used to assess
independent effects of SF analytes and to control for BMI, age,
and gender.
Results: This study was limited to 69 study participants (49
women and 20 men) with knee OA and adequate SF volume for
these analyses. The mean (±SD) age was 64.5±10.1 years. The
mean (±SD) body mass index was 32.4±7.1 kg/m2. Knee OA
was graded 1-4 in severity (23.1%, 14.6%, 49.2%, 13.1% for each
KL grade). SF measurements were possible for both knees of 63
participants, and for single knees of 6 participants.
The mean UA (±SD) was 6.43±1.75 mg/dl for serum, 5.17±1.79
mg/dl for the right knee SF, and 4.93±1.95 mg/dl for the left knee
SF. Serum UA was highly correlated with SF UA (p<0.0001),
but UA was consistently higher in serum in nearly all individuals
(p<0.0001).
SF UA was associated with increased SF IL-8, a marker of
inﬂammation associated with macrophage activation (p<0.0001),
but did not correlate with other markers in the cytokine panel.
SF, but not serum, UA was positively associated with all three
measures of OA severity.
Relationship between analytes and Knee OA severity (P values)
Late Phase
Bone Scan* JSN OST JSN + OST
Total TF Total TF Total TF Total TF
SF UA 0.04 0.03 0.29 0.05 0.01 0.0003 0.02 0.001
SF lnIL-8 0.06 0.01 0.04 0.007 0.0001 <0.0001 0.002 <0.0001
Serum UA 0.02 0.04 0.08 0.33 0.83 0.63 0.53 0.50
*Early Phase Bone Scan controlled for in model. Total = Tibiofemoral (TF) +
Patellofemoral. JSN = Joint Space Narrowing. OST = Osteophytes.
Multivariate Generalized Linear Modeling (P values)
Outcomes
Late Phase
Bone Scan* JSN OST JSN + OST
Total TF Total TF Total TF Total TF
SF UA 0.02 0.02 0.34 0.06 0.02 0.0006 0.04 0.002
Early Phase <0.0001 <0.0001
BMI <0.0001 0.005 0.15 0.03 0.58 0.58 0.42 0.29
Age 0.03 0.21 0.08 0.13 0.53 0.26 0.33 0.19
Gender 0.41 0.98 0.21 0.17 0.87 0.40 0.83 0.28
*Early Phase Bone Scan controlled for in model. Total = Tibiofemoral (TF) +
Patellofemoral. JSN = Joint Space Narrowing. OST = Osteophytes.
Conclusions: The strong association shown here between OA
severity, particularly osteophytes, and SF UA, demonstrates that
UA is a marker of joint tissue injury and raises the strong possibility
that UA may be a factor contributing to the pathological process
of OA. The constitutive release of UA from injured and dying
cells in the OA joint may exacerbate joint tissue inﬂammation
through sub-acute macrophage activation. Urate crystallization
in the presence of nucleating agents released from degrading
cartilage extracellular matrix may also contribute to joint tissue
inﬂammation.
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Purpose: Biochemical markers of cartilage and bone degradation
are becoming increasingly important in the evaluation of knee
Osteoarthritis (OA). The correlation between radiological knee OA
and urine CTX-II (C-terminal crosslinking telopeptide of collagen
type II) or urine NTX-I (N-terminal crosslinking telopeptide of type
I collagen) needs to be evaluated how these markers are useful in
the health check-up in a large population-based study.
Methods: We have performed the epidemiological knee survey in
a rural Japanese population every 7 years at the Matsudai district
in Niigata Prefecture, Japan since 1979. In 2007 (5th survey), a
cross-sectional study of biomarkers was conducted with informed
consent in the historical cohorts. Urine specimens were collected
from 1040 subjects (605 females and 435 males), and CTX-II and
NTX-I were measured using ELISA. Menstruation status and oral
administration of bisphosphonate were checked. Standing knee
AP X-rays were obtained and graded according to the Kellgren-
Lawrence (K-L) classiﬁcation. The subjects were then divided by
gender, age (40- to 59-year-old group and 60- to 79-year-old
group), and the X-ray grade (K-L Grade 0,1, Grade 2, and Grade
3,4). The values of CTX-II and NTX-I were compared between age
groups and OA grade groups. Mann Whitney U test, Kruskal-Wallis
test, and Spearman’s rank correlation test were used, and p<0.05
was considered statistically signiﬁcant.
Results: In non-OA (Grade 0,1) subjects, there was no signiﬁcant
difference in CTX-II values between two age groups in males.
However, in female, the 40- to 59-year-old postmenopausal group
and the 60- to 79-year-old group had signiﬁcantly higher CTX-II
values than the 40- to 59-year-old premenopausal group. Admin-
istration of bisphosphonate also affected strongly both CTX-II and
NTX-I values, so subjects taking bisphosphonate were excluded
from further analysis.
In the male subjects aged over 60 years, knee OA Grade 3,4
group had signiﬁcantly higher CTX-II values than the Grade 0, 1
group or the Grade 2 group (Fig. 1). In female subjects aged over
60 years, CTX-II values signiﬁcantly increased according to the
severity of knee OA (Fig. 1).
For NTX-I, there were no signiﬁcant differences between each
OA grade. However, weak but positive correlations were observed
between the urine CTX-II and urine NTX-I values in the 40- to 59-
year-old female group and the 60- to 79-year-old male and female
groups (n=151, 352, 418, and rs=0.23, 0.10, 0.14, respectively).
Conclusions: Urine CTX-II can be a useful biomarker of knee
OA stages even by the single measurement in people older than
60 years although it would be difﬁcult for 40-59 year-old people
to evaluate knee OA changes using single urine CTX-II values.
